Mallinckrodt Medical, Inc.

Other

Mallinckrodt, Inc.

Dennis L Nosco

Edward A Deutsch

Karen F Deutsch

Steven R Woulfe

David H White

Robert G Wolfangel

William H Ralston

Janet B Wilking

William P Cacheris

Linda Meeh

Raghavan Rajagopalan

William L Neumann

Mary Marmion Dyszlewski

James W Brodack

Sandeep Nema

Mark A DeRosch

Kofi Adzamli

Richard T Dean

T Jeffrey Dunn

Alfons M Verbruggen

Alexander Lazarevich Klibanov

Julie A Beaty

Alexander L Kilbanov

Dennis Wester

Mark A Derosch

The present invention relates to the stabilization of radiopharmaceutical preparations and to the stabilization of components of radiopharmaceutical kits. In particular, the present invention relates to stabilization of lyophilized components of radiopharmaceutical kits by the addition of a cyclic oligosaccharide, such as, a modified or unmodified cyclodextrin, to the kit.

Stabilized radiopharmaceutical kits

The present invention relates particularly to novel preorganized hexadentate ligands that are suitable for completing with a radionuclide, and are useful as general imaging agents for diagnostic purposes.

Preorganized hexadentate ligands useful in radiographic imaging agents

The present invention relates to novel technetium-99m complexes and to methods of preparing the complexes. The present invention further relates to a radiopharmaceutical compositions comprising the complexes, to the use of the compositions for examining the renal function, and to a kit for preparing such compositions.

Technetium-99m complexes for use as radiopharmaceuticals

Treated apatite particles are disclosed for enhancing medical diagnostic imaging such as magnetic resonance imaging ('MRI'), magnetic resonance spectroscopy ('MRS'), magnetic resonance spectroscopy imaging ('MRSI'), X-ray diagnostic imaging, and ultrasound imaging. Novel coating and manufacturing techniques are disclosed to control particle size and particle aggregation resulting in compositions for organ specific imaging of the liver, spleen, gastrointestinal tract, or tissue disease states is obtained. Depending on the diagnostic imaging technique, apatite particles are treated to be paramagnetic, radiopaque, or echogenic. The apatite particles may also be fluorinated to form stable fluoroapatite compositions useful for .sup.19 F imaging. Also disclosed are diagnostic compositions and methods of performing medical diagnostic procedures which involve administering to a warm-blooded animal a diagnostically effective amount of the above-described apatite particles and then performing the medical diagnostic procedure.

Treated apatite particles for medical diagnostic imaging

The present invention provides new and structurally diverse particulates for use in magnetic resonance imaging and X-ray contrast imaging of body organs and tissues having the following general formula:

Process of preparing coated calcium/oxyanion-containing particles

The present invention relates particularly to novel preorganized hexadentate ligands that are suitable for complexing with a radionuclide, and are useful as general imaging agents for diagnostic purposes.

Treated apatite particles are disclosed for enhancing radical diagnostic imaging such as magnetic resonance imaging ('MRI'), magnetic resonance spectroscopy ('MRS'), magnetic resonance spectroscopy imaging ('MRSI'), X-ray diagnostic imaging, and ultrasound imaging. Novel coating and manufacturing techniques are disclosed to control particle size and particle aggregation resulting in compositions for organ specific imaging of the liver, spleen, gastrointestinal tract, or tissue disease states is obtained. Depending on the diagnostic imaging technique, apatite particles are treated to be paramagnetic, radiopaque, or echogenic. The apatite particles may also be fluorinated to form stable fluoroapatite compositions useful for .sup.19 F imaging. Also disclosed are diagnostic compositions and methods of performing medical diagnostic procedures which involve administering to a warm-blooded animal a diagnostically effective amount of the abovedescribed apatite particles and then performing the medical diagnostic procedure.

Treated apatite particles for ultrasound imaging

Treated calcium/oxyanion-containing particles are disclosed for enhancing medical diagnostic imaging such as magnetic resonance imaging ('MRI'), magnetic resonance spectroscopy ('MRS'), magnetic resonance spectroscopy imaging ('MRSI'), X-ray diagnostic imaging, and ultrasound imaging. Novel coating and manufacturing techniques are disclosed to control particle size and particle aggregation resulting in compositions for organ specific imaging of the liver, spleen, or tissue disease states is obtained. Depending on the diagnostic imaging technique, calcium/oxyanion-containing particles are treated to be paramagnetic, radiopaque, or echogenic. Also disclosed are diagnostic compositions and methods of performing medical diagnostic procedures which involve administering to a warm-blooded animal a diagnostically effective amount of the above-described particles and then performing the medical diagnostic procedure.

Treated calcium/oxyanion-containing particles for medical diagnostic

The present invention provides radiation synovectomy compositions for treating inflamed synovium containing a radionuclide complex bound to a hydroxyapatite-like matrix as the radiolabelled synovectomy agent in a sufficient amount to provide satisfactory synovectomy of the inflamed synovium together with a pharmaceutically acceptable vehicle, the radionuclide being a beta emitter that will substantially ablate the inflamed synovium, but not significantly damage underlying articular cartilage, the radionuclide complex being substantially kinetically stable, and if said radionuclide or radionuclide complex leaks from said joint it will be excreted from the body, the agent having a particle size such that there is essentially little or no leakage of the radionuclide complex from the joint after administration.

Radionuclide labelled particles useful for radiation synovectomy

Calcium/oxyanion-containing particles with a polymerical alkoxy coating

Treated apatite particles are disclosed for enhancing medical diagnostic imaging such as magnetic resonance imaging ('MRI'), magnetic resonance spectroscopy ('MRS'), magnetic resonance spectroscopy imaging (37 MRSI'), X-ray diagnostic imaging, and ultrasound imaging. Novel coating and manufacturing techniques are disclosed to control particle size and particle aggregation resulting in compositions for organ specific imaging of the liver, spleen, gastrointestinal tract, or tissue disease states is obtained. Depending on the diagnostic imaging technique, apatite particles are treated to be paramagnetic, radiopaque, or echogenic. The apatite particles may also be fluorinated to form stable fluoroapatite compositions useful for .sup.19 F imaging. Also disclosed are diagnostic compositions and methods of performing medical diagnostic procedures which involve administering to a warm-blooded animal a diagnostically effective amount of the abovedescribed apatite particles and then performing the medical diagnostic procedure.

Treated apatite particles for x-ray diagnostic imaging

Technetium-99M complexes for use as radiopharmaceuticals

The present invention relates to novel compounds for use as imaging agents. In particular, the present invention relates to imaging agents comprising a heavy metal cluster having 2 to 8 atoms of the same of different heavy metal elements, and at least one coordinating ligand having 1 to 8 atoms which bond to the cluster, and a number of supporting atoms making up the framework of the ligand.

Heavy metal clusters for use as imaging agents

The present invention relates to novel compounds for use as imaging agents. In particular, the present invention relates to paramagnetic metal clusters having oxygen and/or nitrogen containing ligands useful as contrast agents for magnetic resonance imaging (MRI).

Growing community of inventors

Florissant, MO, United States of America

Dennis L Nosco